Physician profile
J Patrick Waring
NPI 1174527741
$1,101.23
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $215 · 2021: $223 · 2022: $321 · 2023: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $118.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.35 | 2019-2023 | Linzess, Creon, Viberzi |
| Medtronic, INC. | $168.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.14 | 2019-2022 | |
| Medtronic USA, INC. | $76.88 | 2019-2020 | |
| Covidien LP | $62.36 | 2020 | |
| Janssen Biotech, INC. | $61.65 | 2019-2023 | Remicade, Simponi, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $51.73 | 2019-2023 | Entyvio |
| Ironwood Pharmaceuticals, INC | $41.79 | 2019-2022 | |
| Redhill Biopharma INC. | $33.37 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $25.20 | 2023 | Dupixent |
| Allergan, INC. | $24.52 | 2019 | |
| Amgen INC. | $23.89 | 2022 | |
| Genzyme Corporation | $20.61 | 2022 | |
| Merck Sharp & Dohme LLC | $19.42 | 2022 | |
| Braintree Laboratories, INC. | $16.96 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $14.09 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Waring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.